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Protocol
AbstrACt
Introduction A retained placenta is diagnosed when the 
placenta is not delivered following delivery of the baby. It 
is a major cause of postpartum haemorrhage and treated 
by the operative procedure of manual removal of placenta 
(MROP).
Methods and analysis The aim of this pragmatic, 
randomised, placebo-controlled, double-blind 
UK-wide trial, with an internal pilot and nested 
qualitative research to adjust strategies to 
refine delivery of the main trial, is to determine 
whether sublingual glyceryl trinitrate (GTN) is (or 
is not) clinically and cost-effective for (medical) 
management of retained placenta. The primary 
clinical outcome is need for MROP, defined as the 
placenta remaining undelivered 15 min poststudy 
treatment and/or being required within 15 min of 
treatment due to safety concerns. The primary 
safety outcome is measured blood loss between 
administration of treatment and transfer to the 
postnatal ward or other clinical area. The primary 
patient-sided outcome is satisfaction with treatment 
and a side effect profile. The primary economic 
outcome is net incremental costs (or cost savings) 
to the National Health Service of using GTN versus 
standard practice. Secondary outcomes are being 
measured over a range of clinical and economic 
domains. The primary outcomes will be analysed 
using linear models appropriate to the distribution of 
each outcome. Health service costs will be compared 
with multiple trial outcomes in a cost-consequence 
analysis of GTN versus standard practice.
Ethics and dissemination Ethical approval has been 
obtained from the North-East Newcastle & North Tyneside 
2 Research Ethics Committee (13/NE/0339). Dissemination 
plans for the trial include the Health Technology 
Assessment Monograph, presentation at international 
scientific meetings and publication in high-impact, peer-
reviewed journals.
trial registration number ISCRTN88609453; Pre-results.
IntroduCtIon
background
A retained placenta (RP) is diagnosed when 
the placenta is not delivered within 30 or 
60 min after delivery of the baby following 
active or physiological management of the 
third stage of labour, respectively1 and is a 
major cause of postpartum haemorrhage.2 3 
The incidence of retained placenta is rising 
in the UK due to changes in maternal demo-
graphics, increased intrapartum interven-
tions and operations involving exploration 
of the uterine cavity including surgical termi-
nation of pregnancy and dilation and curet-
tage.4 Retained placenta currently affects 
approximately 2% of vaginal deliveries4 which 
equates to nearly 11 000 women per annum 
in the UK. Following failure of active or phys-
iological management, the National Institute 
of Health and Care Excellence recommends 
strengths and limitations of this study
 ► Pragmatic randomised placebo-controlled double-
blind UK-wide trial to determine whether sublingual 
glyceryl trinitrate is (or is not) clinically and cost-
effective for (medical) management of retained 
placenta.
 ► Inclusion of clinical, patient-sided, safety and 
economic outcomes with minimal exclusion criteria.
 ► Pragmatic approach to obtaining consent and 
good clinical practice (GCP)-training to facilitate 
recruitment in the emergency setting.
 ► Fully adaptive group sequential design.
 ► Inability to differentiate whether a placenta is 
adherent or trapped prior to administration of study 
drug.
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that retained placenta should be treated by the opera-
tive procedure of manual removal of placenta (MROP).1 
This procedure requires skilled personnel, an operative 
environment and, compared with spontaneous placental 
delivery, has its own attendant risks, including bleeding3 
and infection.5 There is often a delay in undertaking the 
operation, which leads to further haemorrhage,6 and the 
procedure itself is costly in terms of staff time. Further-
more, the infrastructure required for this operative inter-
vention is not available in all delivery settings, and the 
invasive nature of this procedure has the potential to delay 
or interrupt mother–baby bonding in the immediate 
postpartum period. To reduce the number of women 
requiring MROP, there is therefore a need for new (and 
effective) medical treatments for retained placenta. The 
reduction in operative interventions would potentially 
have cost benefits for the National Health Service (NHS) 
and also for women in terms of increased satisfaction, less 
separation between mother and baby immediately after 
birth and reduced morbidity.
rationale for study
Observational studies along with results from small 
randomised controlled trials have suggested that nitric 
oxide donors including glyceryl trinitrate (GTN) given 
intravenously might be effective for the management 
of retained placenta with success rates ranging between 
94% and 100%.7–10 Although intravenous GTN appears 
to be efficacious for retained placenta in these small 
studies, this route of administration is not practical in 
all settings and intravenous administration causes unac-
ceptable side-effects including symptomatic hypotension 
at higher doses.3 More recently, sublingual administra-
tion has been trialled, with studies reporting experience 
with sublingual GTN tablet and spray. Using a sublingual 
GTN tablet, two small studies suggest a beneficial effect of 
sublingual GTN tablet; however, a third larger study does 
not (ISRCTN34755982; 37.3% vs 20.4%; GTN vs placebo; 
p>0.05; n=105 women).11 The alternative preparation 
for sublingual administration is GTN spray.12 Compared 
with the tablet preparation, sublingual GTN spray has 
several advantages including stability at room tempera-
ture, significant reduction in latency of onset with onset 
beginning at 30–45 s, peaking at 90–120 s and lasting up 
to 5 min,13–15 and fewer objective and subjective side-ef-
fects.16 GTN spray is an accepted obstetric management 
in other scenarios where rapid tocolysis is required such 
as uterine relaxation for release of a trapped head in 
breech delivery or at caesarean section.12 Furthermore, 
anecdotal reports suggest that GTN spray may also have a 
use in management of retained placenta.12
To summarise, although a growing body of evidence 
supports GTN use for the treatment of retained placenta, 
much of this evidence is based on anecdotal case reports or 
clinical studies which are non-randomised, do not include 
a placebo arm and are underpowered. There is therefore 
a need to undertake a well-designed, randomised, place-
bo-controlled, double-blind pragmatic group sequential 
UK-wide (GOT-IT trial) to definitively determine whether 
sublingual GTN is (or is not) clinically and cost-effective 
for management of retained placenta.
study objectives
The aim of this placebo-controlled, double-blind, prag-
matic group sequential UK-wide trial is to determine the 
effectiveness and cost-effectiveness of GTN for treating 
retained placenta and avoiding MROP.
The hypothesis being tested is that sublingual GTN 
spray is clinical and cost effective in treating retained 
placenta after vaginal delivery, reducing the need for 
MROP following failure of current management.
The primary objectives are to: (1) determine the clin-
ical effectiveness of sublingual GTN in treating retained 
placenta and avoiding MROP in women with vaginal 
delivery following failure of current management (clin-
ical domain), (2) determine the side-effect profile for 
GTN given to treat retained placenta (safety domain), 
(3) assess patient satisfaction with GTN given for retained 
placenta (patient-sided domain) and (4) assess the net 
costs (or cost savings) to the NHS of using GTN for the 
treatment of retained placenta compared with standard 
practice (economic domain).
The secondary objectives are to assess NHS costs in relation 
to the primary outcome and range of secondary outcomes 
which are expected to differ between the two arms of the 
trial, using a cost-consequence balance sheet approach.
The trial contained an internal pilot, which commenced 
in October 2014 and was completed in April 2015. The aim 
of this internal pilot, which recruited from eight sites across 
the UK, was to provide reassurance on all the trial processes, 
including recruitment, consent, randomisation, delivery of 
treatment and follow-up assessments to ensure that all were 
running smoothly. Recruitment to the substantive trial is 
ongoing and is due to finish in September 2017.
A nested qualitative study was undertaken during 
the internal pilot to adjust strategies to (1) maximise 
recruitment into the main trial, (2) refine the recruit-
ment and consent pathway and (3) ensure staff are given 
appropriate training and support to help promote the 
successful delivery of the main trial. In-depth qualitative 
interviews were undertaken with staff (n=27) involved in 
trial recruitment, consenting and/or trial delivery and 
with trial recruits (n=22) within, when possible, 4 weeks 
of randomisation. The results of the qualitative research 
have been published and have informed the delivery of 
the main trial.17 18
MEthods And AnAlysIs
study design
This is a placebo-controlled, double-blind, pragmatic 
group sequential UK-wide trial to determine the effective-
ness of GTN for treating retained placenta and avoiding 
MROP. Women are identified as being potentially eligible 
for the trial if, following vaginal birth, they have a retained 
placenta and are at risk of needing a MROP after failure 
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of current management of the third stage of labour. If 
eligible for the trial, women are treated with either 
the study drug or a placebo in a double-blind fashion. 
Following administration of the study medication, if 
the placenta still remains undelivered after 15 min, the 
treating clinician determines ongoing clinical manage-
ment as per standard care.
The prespecified group sequential monitoring plan 
requires the Data Monitoring Committee to look at accu-
mulating unblinded data on five occasions. The Data 
Monitoring Committee is using the results of these anal-
yses to advise the Trial Steering Committee on adapting 
the trial design to either (1) stop prematurely for futility 
(no prospect of establishing a treatment effect of at least 
10%) or (2) stop prematurely if proof beyond a reason-
able doubt is established that there is a convincing treat-
ment benefit of at least 10%. Assuming the trial recruits 
to its maximum size, we are aiming to recruit 1100 partic-
ipants (maximum number randomised 1086, with the 
uplift to 1100 to account for a small allowance for with-
drawal of consent or other rare loss to follow-up) over 42 
months.
study population
Setting
We are recruiting women from delivery wards in UK 
maternity hospitals. The delivery wards are of varying 
size and location ensuring the results of the trial will be 
generalisable to the UK. At present, recruitment is being 
undertaken in 28 sites across the UK.
Selection of participants
As is standard practice, clinicians are undertaking the 
initial eligibility screening. Women are identified as being 
potentially eligible for the trial if, following vaginal birth, 
they have a retained placenta and are at risk of needing 
a MROP after failure of current management of the 
third stage of labour, defined as the placenta remaining 
undelivered after (1) 30 min of active management or 
(2) 60 min of physiological management plus a further 
30 min of active management of the third stage of labour.
Planned inclusion and exclusion criteria
All women will be considered for the trial who have RP 
after vaginal birth following failure of current manage-
ment (defined as a third stage of labour lasting more 
than (1) 30 min after active management or (2) 60 min 
following physiological followed by 30 min of active 
management. In addition, they should also satisfy the 
following inclusion criteria. Should a woman have any of 
the exclusion criteria, they will not be invited to partici-
pate in the trial.
Women are eligible for inclusion if they are:
 ► Aged ≥16 years
 ► Vaginal delivery (including women with a previous 
caesarean section and an instrumental vaginal delivery 
in the delivery room)
 ► >14 weeks gestation
 ► Haemodynamically stable, defined as having a heart 
rate ≤119 beats per minute and a systolic blood pres-
sure of >100 mm Hg
Exclusion criteria
Women are excluded if they have one or more of the 
following:
 ► Unable to give informed consent
 ► Suspected placenta accreta/increta/percreta
 ► Multiple pregnancy
 ► Allergy or hypersensitivity to nitrates
 ► Consumption of alcohol in the last 24 hours
 ► Concomitant use of phosphodiesterase inhibitors
 ► Instrumental vaginal delivery in theatre
 ► Contraindications to nitrates including severe 
anaemia, constrictive pericarditis, extreme brady-
cardia, incipient glaucoma, glusose-6-phosphate dehy-
drogenase–deficiency, cerebral haemorrhage and 
brain trauma, aortic and/or mitral stenosis, angina 
caused by hypertrophic obstructive cardiomyopathy, 
circulatory collapse, cardiogenic shock and toxic 
pulmonary oedema
recruitment and study procedures
Identifying participants
Recruitment was initiated in October 2014 and is currently 
ongoing in the delivery wards of 28 UK maternity hospi-
tals. Recruitment is scheduled to conclude when 1100 
subjects are recruited to the trial.
We initially followed the Royal College of Obstetrics 
and Gynaecology best practice recommendations for 
recruitment and obtaining consent for intrapartum 
research studies.19 These recommendations were based 
on the work by Vernon et al,20 who developed a consent 
pathway for women with retained placenta who were 
recruited to the RELEASE trial of umbilical vein oxytocin 
for RP.21 We refined this pathway in light of our quali-
tative research17 18 so that the consent and recruitment 
pathways were tailored to the specific requirements of 
this trial. In brief, where possible, outline information 
about the trial (including researcher contact details) is 
made available to women antenatally, particularly those 
identified as being at high risk of retained placenta, 
for example, maternal age >30 years, preterm birth and 
stillbirth.22 More detailed information is available in 
antenatal clinics, on labour wards and the study website 
with information posters in the hospital reception areas 
and antenatal clinics. Following diagnosis of a retained 
placenta, a clinician or midwife who has received GOT-IT 
study training (which has sponsor-approved GCP-training 
embedded within it) invites women to participate in 
the trial, provides an explanation of the study and gives 
potential participants an abbreviated and/or full version 
of the patient information sheet.
Informed consent
The patient information leaflets explain that the trial 
is investigating whether sublingual GTN spray is useful 
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for treating retained placenta. If a woman wishes to 
participate then written or verbal consent is obtained. If 
verbal consent is obtained, this is followed up by written 
consent as soon as possible in the postnatal period. Such 
an approach has been endorsed by the Royal College 
of Obstetricians and Gynaecologists in recent guidance 
about obtaining consent in perinatal research where 
consent is time critical in which it is stated that ‘[in 
acute circumstances]…provision of antenatal informa-
tion to women with brief oral consent at the time of the 
complication is appropriate. Full written consent is then 
obtained at a later stage’.23 Permission is sought to inform 
the woman’s general practitioner that she is taking part 
in this trial. Due to the emergency nature of the condi-
tion (retained placenta), women are eligible to take part 
if they fulfil the inclusion criteria, understand what trial 
participation involves and give fully informed consent. A 
minimum time period is not feasible for trial consider-
ation by potential participants. If a woman cannot give 
informed consent (eg, due to incapacity), she is not 
eligible for participation.
Randomisation and allocation
The study drug is a metered dose sublingual spray 
containing 400 µg/dose of GTN and a matching placebo 
spray. The formulation consists of GTN, peppermint oil 
BP (88%), 1,1,1,2-tetrafluoroethane (HFA) and ethanol 
BP (96%). The placebo is identical to the active product 
minus the GTN. Both the study drug and the matching 
placebo are manufactured by Pharmasol Limited and 
labelled by Sharp Clinical Services (UK) Limited.
Study drugs are kept on the delivery suite and are 
provided to site pharmacies in prepacked randomised 
permuted blocks. After consent of each participant, the 
investigator or trained clinical practitioner randomises 
eligible and consenting women to one of the two study 
groups by taking the next box off the shelf. After priming 
the pump and demonstrating its use, the clinician gives 
the study drug to the women to self-administer. The study 
is double-masked, so neither the participant, investigator 
nor trained clinical practitioner know which treatment 
has been allocated. The boxes are numbered and labelled 
so that the identity of the drug can be determined later. 
The number on the box is logged in the study database. 
Breaking of the study masking is only performed where 
knowledge of the treatment is absolutely necessary for 
safe management of the patient.
A central emergency unblinding interactive voice 
response system is operated by the Centre for Healthcare 
Randomised Trials (ChaRT) in Aberdeen. Only senior 
clinicians can unblind trial participants. The name of 
the clinician requesting the unblinding, the reasons 
for it and notification of any unblinding is sent to the 
chief investigator via email. Reasons for unblinding are 
recorded in the participant’s sources documents and in 
the Investigator Site Master File. Unless there is a clinical 
requirement, masking will not be broken until after all 
study data entry is complete, the validity of the data is 
checked, all queries resolved and the patient populations 
agreed.
Administration of study intervention
Women who have a retained placenta after vaginal birth 
or miscarriage following failure of management of the 
third stage of labour (failure of active management 
defined as the third stage lasting more than 30 min and 
failure of physiological management defined as the third 
stage lasting more than 60 min, plus a further 30 min of 
active management) are considered for eligibility for the 
trial.
Baseline observations (maternal blood pressure 
(mm Hg) and heart rate (beats per minute)) are taken 
prior to study drug administration to confirm that the 
woman fulfils the haemodynamic inclusion criteria (heart 
rate ≤119 bpm and systolic blood pressure >100 mm Hg) 
for trial entry.
Following confirmation of eligibility, women self-ad-
minister two puffs of either GTN (800 µg) or placebo 
spray as a once-only, sublingual intervention via a pump 
spray. Maternal temperature and a blood sample to 
measure haemoglobin are measured at baseline. Heart 
rate, systolic blood pressure and temperature (oC) are 
recorded at 5 and 15 min after administration of the study 
drug.
Sublingual GTN is maximally effective in causing 
uterine and cervical relaxation by 5 min postadminis-
tration. Thus, if spontaneous delivery of the placenta is 
going to occur, we expect this to happen around 5 min 
after drug administration. If spontaneous placental 
delivery has not occurred, a further attempt to deliver 
the placenta by controlled cord traction is made. If the 
placenta remains undelivered 15 min after administra-
tion of the treatment we think that it is highly unlikely 
that it will deliver spontaneously thereafter—we consider 
that any further delay risks haemorrhage. Thus, the deci-
sion that MROP is needed (primary clinical outcome) is 
made and the participant transferred to theatre for the 
definitive management of MROP as soon as possible. 
Additionally, if there are clinically significant side-effects 
(eg, haemorrhage, symptomatic maternal hypotension 
and/or tachycardia) before 15 min have elapsed after 
GTN/placebo treatment, the participant is transferred to 
theatre for immediate MROP.
Follow-Up procedures
On the first postnatal day, a haemoglobin sample is 
collected. A questionnaire relating to the woman’s 
perception of the study drug in relation to side-effects 
and patient satisfaction is also completed. A second ques-
tionnaire is sent by the Central Trial Office to participants 
at 6-week postdelivery. The questionnaire collects further 
information on patient-rated side-effects, patient-rated 
satisfaction and health economic resource use.
Women remain in the trial unless they are unable to 
continue for a clinical reason or choose to withdraw 
consent. All other changes in status, with the exception of 
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formal withdrawal of consent, mean the participant will 
be followed up for all study outcomes whenever possible.
safety
The laws that govern reporting for clinical trials of inves-
tigational medicinal products (IMP) regulate safety 
reporting for the GOT-IT trial. Adverse events (AEs) may 
occur during or after participation in the trial.
Definitions
An AE is any untoward medical occurrence in a clinical 
trial participant which does not necessarily have a causal 
relationship with an IMP. Each AE is considered for 
severity, causality or expectedness and may be reclassified 
as a serious event.
An adverse reaction (AR) is any untoward and unin-
tended response to the IMP which is related to any dose 
administered to that participant.
A serious adverse event (SAE) and serious adverse reac-
tion (SAR) is any AE or AR that at any dose:
 ► results in death of the clinical trial participant;
 ► is life-threatening, defined as an event where the 
participant was at risk of death at the time of the 
event. It does not refer to an event which hypothet-
ically might have caused death if it were more severe;
 ► requires inpatient hospitalisation or prolongation of 
existing hospitalisation;
 ► results in persistent or significant disability or 
incapacity;
 ► consists of a congenital anomaly or birth defect;
 ► results in any other significant medical event not 
meeting the criteria above.
A suspected unexpected serious adverse reaction 
(SUSAR) is any AR that is classified as serious and is 
suspected to be caused by the IMP, that it is not consistent 
with the information about the IMP in the summary of 
the medicinal product characteristics (SmPC).
Identifying AEs and SAEs
All AEs and SAEs are recorded from the time a partici-
pant signs the consent form to take part in the study until 
the 6-week postnatal outcome assessment point.
Participants are asked about the occurrence of AEs/
SAEs prior to discharge from the hospital and in the 
6-week postnatal questionnaire. Open-ended and 
non-leading verbal questioning of the participant are 
used to enquire about AE/SAE occurrence at discharge. 
The 6-week postnatal questionnaire also asks participants 
if they have seen their general practitioner, been admitted 
to hospital or been prescribed any medication. If there is 
any doubt as to whether a clinical observation is an AE, 
the event is recorded. AEs and SAEs are also identified 
via information from support departments, for example, 
laboratories.
Recording AEs and SAEs
When an AE/SAE occurs, it is the responsibility of the 
principal investigator to review all documentation (eg, 
hospital notes, laboratory and diagnostic reports) related 
to the event. The principal investigator records all rele-
vant information on the SAE form (if the AE meets the 
criteria of SAE). Information to be collected includes 
type of event, onset date, Investigator assessment of 
severity and causality, date of resolution as well as treat-
ment required, investigations needed and outcome.
The clinician will assess all reported SAEs. The events 
detailed in the list below are ‘expected’ and will not be 
reported to the cosponsors as an SAE but will be recorded 
in the case report form as a hospitalisation or outcome 
and presented to the Data Monitoring Committee, as part 
of the ongoing safety review.
In this trial, the following events are not considered 
SAEs: (1) pregnancy is not considered an AE or SAE, as it is 
part of the inclusion criteria; (2) hospitalisations for treat-
ment planned prior to randomisation and hospitalisation 
for elective treatment of a pre-existing condition will not 
be considered as an SAE. This includes pregnancy; (3) 
fall in haemoglobin of more than 15% between recruit-
ment and the first postnatal day; (4) MROP in theatre; 
(5) need for earlier than planned MROP on the basis 
of the clinical condition; (6) fall in systolic or diastolic 
blood pressure of more than 15 mm Hg and/or increase 
in pulse of more than 20 beats/min between baseline and 
5 min and 15 min postadministration of active/placebo 
treatment; (7) need for blood transfusion between time 
of delivery and discharge from hospital; (8)_need for 
general anaesthesia; (9) maternal fever (one or more 
temperature reading of more than 38°C within 72 hours 
of delivery or discharge from hospital if discharge occurs 
sooner); (10) sustained uterine relaxation after removal 
of placenta requiring uterotonics.
Assessment of AEs and SAEs
Seriousness, causality, severity and expectedness of each 
AE are assessed by the principal investigator. AEs are 
assessed as though the participant is taking active IMP. 
Cases that are considered serious, possibly, probably or 
definitely related to IMP and unexpected (ie, SUSARs) 
are unblinded. This may be delegated to other suitably 
qualified physicians in the research team who are trained 
in recording and reporting AEs. The chief investigator 
may not downgrade an event that has been assessed by an 
investigator as an SAE or SUSAR, but can upgrade an AE 
to an SAE, SAR or SUSAR if appropriate.
Assessment of seriousness
The investigator makes an assessment of seriousness as 
defined in Definitions section.
Assessment of causality
The investigator makes an assessment of whether the AE/
SAE is likely to be related to the IMP according to the 
definitions below.
 ► Unrelated: where an event is not considered to be 
related to the IMP.
 ► Possibly related: the nature of the event, the under-
lying medical condition, concomitant medication or 
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temporal relationship make it possible that the AE 
has a causal relationship to the study drug. The assess-
ment of causality is made against the reference safety 
information found in the SmPC.
Where non-investigational medicinal products 
(NIMPs), for example, rescue/escape drugs are given: 
if the AE is considered to be related to an interaction 
between the IMP and the NIMP, or where the AE might 
be linked to either the IMP or the NIMP but cannot be 
clearly attributed to either one of these, the event will be 
considered as an AR. Alternative causes such as natural 
history of the underlying disease, other risk factors and 
the temporal relationship of the event to the treatment 
are considered and investigated; however, the blind will 
not be broken for the purpose of making this assessment.
Assessment of expectedness
If an event is judged to be an AR, the evaluation of expect-
edness will be made based on knowledge of the reaction 
and the relevant product information documented in the 
SmPC. Events are classed as either expected (the AR is 
consistent with the toxicity of the IMP listed in the SmPC) 
or unexpected (the AR is not consistent with the toxicity 
in the SmPC).
Assessment of severity
The investigator makes an assessment of severity for each 
AE/SAE and records this on the SAE form according to 
one of the following categories:
 ► Mild: an event that is easily tolerated by the partici-
pant, causing minimal discomfort and not interfering 
with every day activities.
 ► Moderate: an event that is sufficiently discomforting 
to interfere with normal everyday activities.
 ► Severe: an event that prevents normal everyday 
activities.
Reporting of SAEs/SAR/SUSARs
Once the investigator becomes aware that an SAE has 
occurred in a study participant, the information is 
reported to the Academic and Clinical Central Office for 
Research and Development (ACCORD) Research Gover-
nance and Quality Assurance Office (Edinburgh Univer-
sity and NHS Lothian) immediately or within 24 hours. If 
the Investigator does not have all information regarding 
an SAE, they should not wait for this additional informa-
tion before notifying ACCORD. The SAE report form can 
be updated when the additional information is received.
The SAE report provides an assessment of causality 
and expectedness at the time of the initial report to 
ACCORD. Where missing information has not been sent 
to ACCORD after an initial report, ACCORD contacts the 
investigator and requests the missing information until 
this is supplied.
All reports sent to ACCORD and any follow-up infor-
mation are retained by the investigator in the Investigator 
Site File. ACCORD also informs the trial office who check 
that the SAE is added to the CHaRT database.
Regulatory reporting requirements
The ACCORD Research Governance and Quality 
Assurance Office is responsible for pharmacovigilance 
reporting on behalf of the cosponsors (Edinburgh 
University and NHS Lothian). The ACCORD Research 
Governance and Quality Assurance Office has a legal 
responsibility to notify the regulatory competent authority 
and the Research Ethics Committee that approved the 
trial. Fatal or life-threatening SUSARs are reported no 
later than seven calendar days and all other SUSARs are 
reported no later than 15 calendar days after ACCORD is 
first aware of the reaction. ACCORD informs investigators 
at participating sites of all SUSARs and any other arising 
safety information. An Annual Safety Report/Develop-
ment Safety Update Report is submitted, by ACCORD, to 
the regulatory authorities and Research Ethics Commit-
tees listing all SARs and SUSARs.
Follow-up procedures
After initially recording an AE or recording and reporting 
an SAE, the investigator follows each participant until 
resolution or death of the participant. Follow-up infor-
mation on an SAE is reported to the ACCORD office. 
AEs still present in participants at the 6-week postnatal 
outcome assessment point are monitored until resolution 
of the event or until no longer medically indicated.
outcome measures
The GOT-IT trial is assessing whether sublingual GTN 
spray is clinically and cost-effective in treating retained 
placenta after vaginal delivery, reducing the need for 
MROP following failure of current management.
Primary outcome measures
The primary outcome is measured over four interrelated 
domains of clinical, safety, patient-sided and economic.
The primary clinical outcome is needed for MROP, 
defined as the placenta remaining undelivered 15 min 
poststudy treatment and/or being required within 15 min 
of treatment due to safety concerns.
The primary safety outcome is measured blood loss 
between administration treatment and transfer to the 
postnatal ward or other clinical area.
The primary patient-sided outcome is satisfaction with 
treatment, a side effect profile assessed by a questionnaire 
administered at discharge from hospital and a postal 
questionnaire sent to the participant 6-week posthospital 
discharge.
The primary economic outcome is net incremental costs 
(or cost savings) to the NHS of using GTN versus standard 
practice. Costs include GTN (dose and time to admin-
ister drug), monitoring of the woman and delivering the 
placenta if effective, MROP if required and further health 
service resource use to 6 weeks postdischarge.
Secondary outcomes
The secondary endpoints are measured over two interre-
lated domains of clinical and economic outcomes. There 
are no secondary patient-sided or safety outcomes.
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The secondary clinical endpoints include: (1) fall in 
haemoglobin of more than 15% between recruitment 
and the first postnatal day; (2) time from randomisation 
to delivery of placenta; (3) MROP in theatre; (4) need for 
earlier than planned MROP on the basis of the clinical 
condition, (5) fall in systolic or diastolic blood pressure 
of more than 15 mm Hg and/or increase in pulse of more 
than 20 beats/minute between baseline and 5 min and 
15 min postadministration of active/placebo treatment; 
(6) need for blood transfusion between time of delivery 
and discharge from hospital; (7) need for general anaes-
thesia; (8) maternal fever (one or more temperature 
reading of more than 38°C within 72 hours of delivery 
or discharge from hospital if discharge occurs sooner); 
(9) sustained uterine relaxation after removal placenta 
requiring uterotonics; (10) readmission to hospital for 
any reason within 6-week postpartum.
Estimated health service costs will be compared with 
multiple trial outcomes in a cost-consequence analysis 
of GTN versus standard practice. The costs and conse-
quences of the alternative approaches to treatment will 
be summarised using a balance sheet, highlighting the 
costs and outcomes favouring each treatment option.
data collection and processing
Collection of outcome data
The primary clinical outcome (need for MROP, defined 
as the placenta remaining undelivered 15 min post-treat-
ment and/or being required within 15 min of treatment 
due to safety concerns) is collected 15 min postadmin-
istration of the study drug. The primary safety outcome 
(measured blood loss between administration treatment 
and transfer to the postnatal ward/other clinical area) 
is recorded immediately prior to transfer from theatre 
to the postnatal ward or other clinical area (eg, labour 
ward high dependency). The primary patient satisfac-
tion outcome is collected at 6 weeks by a self-completed 
satisfaction questionnaire and the primary economic 
outcome will be computed from costs incurred at initial 
management of retained placenta and management of 
further complications and self-reported health service 
usage and side-effects recorded from the postnatal patient 
questionnaires.
Outcome data are collected on an electronic case 
report form and paper-based questionnaires by research 
midwives and nurses who have been specifically trained 
in data collection for the trial. The electronic case record 
form comprises the following sections: baseline data, clin-
ical observations and placenta delivery, first post natal 
day, discharge, 6-week postnatal check, safety events, 
discharge and follow-up questionnaires. Health service 
use in the 6 weeks following discharge is collected via a 
small number of resource use questions included in the 
postnatal questionnaires. Resource use will be evaluated 
using routine sources of nationally relevant unit costs. 
Women are permitted to receive all standard care medical 
treatments for postpartum complications including any 
given for medical management of retained placenta. 
Concomitant medications are recorded from 24 hours 
prior to signing of the consent forms until 24 hours after 
administration of the study drug. Analgesic or antibiotic 
medications are recorded from 24 hours prior to signing 
of informed consent until 6 weeks after administration of 
study drug.
sample size, proposed recruitment rate and milestones
Sample size
The trial uses a group sequential design as opposed to a 
fixed sample design to allow for the uncertainty of two 
critical factors. First, there is considerable uncertainty 
about how many women who are eligible for the trial 
will actually go on and require surgery due to (1) lack of 
knowledge of the frequency of spontaneous delivery of 
the placenta beyond the time frame that GTN is known 
to have a pharmacological effect and (2) the effect of vari-
ations in local clinical practice in relation to organising 
MROPs. Second, the magnitude of the benefit from GTN 
spray is unknown. To properly reflect these uncertainties, 
we are using a group sequential design. This design maxi-
mises our chances of efficiently detecting and estimating 
the true benefit of treatment in the quickest time with the 
right number of participants and gives us the opportu-
nity to abandon the trial if it turns out that no worthwhile 
treatment effect exists (via futility analyses).
In discussion with clinicians and women, a minimally 
clinically important difference of an absolute reduction 
of 10% in the need for MROP would need to be observed 
in order to accommodate this intervention (sublingual 
GTN) in clinical practice. Given that the maximum vari-
ability in a binary outcome (yes or no) occurs at a 50% 
rate in the placebo spray arm, a fixed sample approach 
would need 1038 women (519 in each group) to demon-
strate a 10% change from 50% on placebo to 40% on 
GTN spray. As the outcome (surgery occurred—yes or 
no) takes place 15 min after the intervention has been 
administered, there will be minimal loss to follow-up 
and, therefore, no requirement for a trial much larger 
than this. Using a group sequential design incorporating 
a Lan-DeMets alpha spending function with O’Brien-
Fleming boundaries, our trial has a maximum sample size 
of 1086 (with a small inflation to 1100 to allow for with-
drawal of consent of other rare loss to follow-up). This 
allows for five planned interim evaluations by the Data 
Monitoring Committee of accruing data at 218, 436, 652 
and 870 participants with a final look (if the trial proceeds 
to full size) at 1086 women.
Analyses plan
Statistical analysis
The statistical analyses will be according to the intention-
to-treat principle and will be governed by a statistical 
analysis plan which will govern all statistical aspects of 
the study, including the statistical methods for the anal-
ysis of all the outcomes, approaches to missing data and 
sensitivity type analyses to investigate the robustness of 
any findings reported. The statistical analysis plan will be 
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finalised (including the decision to undertake prespec-
ified subgroup analyses or not) prior to the data being 
locked for final analysis. The interim analyses will be spec-
ified within the Data Monitoring Committee Charter and 
the result of the interim analyses will be in strict confi-
dence and unknown to the trial research group apart 
from the study statistician. The primary outcomes, clin-
ical (MROP), safety (blood loss), patient satisfaction and 
economic (NHS costs), will be analysed using generalised 
linear models appropriate to the distribution of each 
outcome. These models will adjust for relevant baseline 
factors, and sensitivity analyses will assess the robustness 
of the findings to any missing data (which is expected to 
be very low as the primary outcome is measured within 
minutes of receiving the intervention). The interim anal-
ysis will be performed in East24 and all remaining anal-
ysis will be done in Stata.25 Significance will be defined 
as p<0.05. In the event prespecified formal subgroup 
analyses of the primary outcome are undertaken, we 
will formally assess subgroup(s) by fitting a subgroup * 
randomised group interaction term and these interac-
tions will be assessed against a stricter level of significance 
of p<0.01 to guard against chance findings.
Economic evaluation
While the cost of GTN is low, there will still be costs asso-
ciated with its administration and the monitoring and 
management of women thereafter. Should the intervention 
prove effective, it will be important in the context of scarce 
maternity resources to explicitly quantify the net costs (or 
cost savings) associated with its use. We have therefore made 
provision to carry out a simple cost analysis using clinical and 
resource use data, which is being collected for individual 
participants recruited to the trial. This analysis will explic-
itly quantify the difference in mean costs between the active 
intervention and placebo arm. Research costs associated 
with placebo delivery will be factored out of the analysis to 
estimate the incremental cost (or cost savings) of the active 
intervention versus standard practice.
Resource use associated with the alternative management 
strategies will be estimated from the time of randomisation 
through to 6 weeks postpartum. This will include: (1) staff 
time for administering the drug to patients; (2) resource 
use associated with any complications arising following 
administration of the study drug (eg, blood pressure and/
or heart rate monitoring); (3) subsequent costs associated 
with delivery of the placenta (either spontaneously or oper-
atively) and (4) subsequent health service contact relating 
to retained products of conception up to 6 weeks postdis-
charge. Resource use collected for individual participants 
will be valued using accepted national unit costs for drugs, 
staff time, MROP and subsequent healthcare contacts.26–28 
The total cost of care for each participant will be calculated 
for each individual.
The mean costs will be summarised by treatment allo-
cation group, and the incremental cost (or cost saving) 
associated with the use of GTN will be estimated using 
an appropriately specified general linear model. The 
cost data will be presented alongside the primary and 
secondary outcome data in a cost-consequence balance 
sheet, indicating which strategy each outcome favours.29
organisation: trial management, oversight and governance 
arrangements
Trial management
The trial is being jointly run by CHaRT based at the Univer-
sity of Aberdeen, the chief investigator and the ACCORD 
office at the University of Edinburgh. The trial management 
and governance are as recommended by The Research 
Governance Framework and The Medicines for Human 
Use (Clinical Trials) Regulations 2004. Briefly, we have 
set up a Trial Steering Committee and a Data Monitoring 
Committee led by individuals independent of the project 
and the institutions involved. The membership of the 
Trial Steering Committee includes independent members 
including a lay representative. A separate and independent 
Data Monitoring Committee has also been convened. The 
Data Monitoring Committee met during trial set-up to agree 
terms of reference and is meeting a further five times during 
recruitment to monitor accumulating data and oversee 
safety issues. The Data Monitoring Committee will meet one 
final time after unblinding to assess overall data validity and 
analyses. The Trial Steering Committee is meeting approxi-
mately seven times with the meeting spacing being matched 
to that of the Data Monitoring Committee. Finally, we have 
regular Project Management Group meetings and Research 
Midwives Meetings to ensure consistency of trial processes 
across sites and share best practice for recruitment, consent 
and data collection.
Research governance and compliance
Research governance
ACCORD is providing oversight that the appropriate 
research and competent authority approvals are in place, 
pharmacovigilance services and is ensuring the trial is 
conducted in accordance with the principles of the Inter-
national Conference on Harmonisation Tripartite Guide-
line for Good Clinical Practice.
Data protection
The trial complies with the Data Protection Act 1998 and 
regular monitoring and checks are in place to ensure 
compliance. Data are being stored in accordance with the 
Act and will be archived to a secure data storage facility. The 
consent form states that other researchers may wish to access 
(anonymised) data in the future. The senior information 
technology manager (in collaboration with the trial statisti-
cian and trial manager) will manage access rights to the data 
set. Prospective new users must demonstrate compliance 
with data protection, legal and ethical guidelines before any 
data are released. We anticipate that anonymised trial data 
will be shared with other researchers to enable international 
prospective meta-analyses.
Sponsorship
The University of Edinburgh and NHS Lothian are the 
cosponsors for the trial. Cosponsorship responsibilities 
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are detailed in an agreement. Responsibilities subcon-
tracted to CHaRT are also detailed in an agreement 
which detail the responsibilities surrounding centralised 
trial administration, database support and economic and 
statistical analyses.
Quality assurance
An independent risk assessment has been performed 
to determine the level of monitoring required and if 
an audit should be performed before/during/after the 
study and if so, at what locations and at what frequency.
Data handling, record keeping and archiving
The local principal investigator or research midwives 
enter locally collected data from the study centres into 
the web-based data collection application. The 6-week 
follow-up questionnaires are sent from and returned to 
the Study Office in Edinburgh and are input by the staff 
in the Study Office in Edinburgh. CHaRT is working with 
the Study Office in Edinburgh and with local Research 
Midwives to ensure that the data are as complete and 
accurate as possible.
EthICs, rEgulAtory ApprovAls And dIssEMInAtIon
Ethics and regulatory approvals
The trial is registered on the International Standard 
Randomised Controlled Trial Number (ISRCTN) as 
ISCRTN88609453. Ethical approval has been obtained 
from the North East- Newcastle & North Tyneside 2 
Research Ethics Committee (13/NE/0339). Approval 
has also been obtained from the Medicines and Health-
care Products Regulatory Authority (MHRA) (2013-
003819-42) and the Health Research Authority as well 
as approvals from the local Trust Research and Devel-
opment Offices. The study has been adopted to the 
National Institute for Health Research Clinical Research 
Network (NIHR CRN) Portfolio (http://www. nihr. ac. 
uk/ research- and- impact/ nihr- clinical- research- network- 
portfolio/). The necessary trial insurance is provided by 
the University of Edinburgh.
dissemination
The dissemination plans include the Health Technology 
Assessment monograph, presentation at international 
scientific meetings and publication of the results of the 
main trial and each of the secondary endpoints in high 
impact peer reviewed journals. If all grant-holders and 
researcher staff fulfil authorship rules, group authorship 
will be used under the collective title of ‘the GOT-IT Trial 
Group’. The chief investigator, trial manager and possibly 
other members of the trial group will take responsibility 
for drafting the paper and this will be recognised by line 
‘the chief investigator (as primary author), followed by 
the other authors and the GOT-IT Trial Group'. Author-
ship of the qualitative substudy publications17 18 has been 
attributed to chief investigator and the named indi-
vidual(s). To maintain interest in the study, we are also 
publishing GOT-IT newsletters at intervals to trial staff 
and collaborators.
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